BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
The FDA approved Foundayo (orforglipron) on April 1, making it the first oral small-molecule GLP-1 receptor agonist for obesity and the only oral GLP-1 that can be taken without food or water restrictions. The approval came under the Commissioner's National Priority Voucher program, just 50 days after filing, making it the fastest NME approval since 2002. Shipping through LillyDirect began April 6. Self-pay pricing starts at $149/month.
Anthropic acquired stealth biotech AI startup Coefficient Bio for approximately $400M in an all-stock deal. The team of fewer than 10 former Genentech computational biologists will join Anthropic's Health Care Life Sciences division.
Takeda (TAK) terminated its 8-year partnership with Denali Therapeutics (DNLI) on a frontotemporal dementia program. Strategic decision, not safety or efficacy related. Denali regains full rights.
Citeline's annual R&D report found the global pharma pipeline contracted for the first time since the mid-1990s: 22,940 drugs in development, down 3.9% from 23,875.
⚡ Executive Takeaway
The biggest oral obesity event of the year happened last week and it landed faster than anyone expected. The FDA approved Lilly's Foundayo (orforglipron) on April 1 under the Commissioner's National Priority Voucher program, 50 days after filing and 294 days before the original PDUFA date. That makes it the fastest new molecular entity approval since 2002. Shipping through LillyDirect started Sunday. Self-pay pricing begins at $149/month at the lowest dose. This is a once-daily oral GLP-1 pill that can be taken any time of day without food or water restrictions, a meaningful convenience advantage over Novo's oral Wegovy, which requires a 30-minute fasting window. The oral GLP-1 war is now officially live. Novo launched its Wegovy pill in January. Lilly has Foundayo shipping within days of approval. Both companies are racing to lock in self-pay patients through DTC channels before the other can build enrollment momentum. 👉 Read Full Analysis
🔮 What To Watch
Foundayo Launch Trajectory: LillyDirect is shipping now. Retail pharmacy and telehealth provider availability will expand rapidly. Watch for initial prescription volume data and how quickly Lilly can scale supply at $149/month.
Novo vs. Lilly Oral GLP-1 Battle: Novo's Wegovy pill is $149/month at the 1.5mg dose. Lilly's Foundayo is $149/month at the lowest dose. The pricing is identical at entry. The differentiation is convenience (Foundayo has no fasting requirement) and weight loss magnitude.
Claude for Life Sciences: Anthropic's Coefficient Bio acquisition means biology-specific AI capabilities are coming to Claude within 12 to 18 months. Sanofi, Novo Nordisk, and AbbVie already use Claude.
Section 232 Tariff Responses: Mid-sized biotechs are beginning to negotiate MFN and onshoring agreements ahead of the September 29 deadline.
🚀 Top Story
Foundayo Is Approved: Lilly's Oral GLP-1 Pill Shipped Within Days of FDA Clearance LLY
What Happened: The FDA approved Foundayo (orforglipron) on April 1, 2026, as the first oral, once-daily, small-molecule GLP-1 receptor agonist for adults with obesity or overweight with at least one weight-related comorbidity. The approval came under the Commissioner's National Priority Voucher (CNPV) pilot program, just 50 days after filing. The original PDUFA date was January 20, 2027. FDA Commissioner Martin Makary called it a demonstration of "what the FDA can achieve when we eliminate delays."
The Data: The ATTAIN Phase 3 program enrolled over 4,500 patients across two global trials. In ATTAIN-1, patients on the highest dose who completed treatment lost an average of 27.3 pounds (12.4% body weight reduction) at 72 weeks versus 2.2 pounds with placebo. The drug also reduced cardiovascular risk markers including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure. ATTAIN-MAINTAIN showed orforglipron was superior to placebo in maintaining weight loss in patients switching from injectable semaglutide or tirzepatide. In the head-to-head ACHIEVE-3 trial versus oral semaglutide, orforglipron 36mg delivered greater A1C reduction (2.2% vs. 1.4%) and weight loss (19.7 lbs vs. 11.0 lbs).
The Launch: Foundayo is available immediately through LillyDirect, with shipping beginning April 6. Broad retail pharmacy and telehealth availability will follow. Pricing: $25/month for eligible patients with commercial insurance, $149/month self-pay at the lowest dose (with higher doses up to $399/month). Medicare Part D pricing of $50/month is targeted for July 2026. Lilly has submitted for approval in more than 40 countries.
Executive Impact: This approval fundamentally changes the competitive dynamics of the oral GLP-1 market. Foundayo can be taken any time of day without food or water restrictions, a significant convenience advantage over Novo's oral Wegovy (which requires 30 minutes of fasting). Lilly CEO David Ricks noted that fewer than one in ten people who could benefit from GLP-1 therapy are currently taking one. With Foundayo at $149/month, Wegovy pill at $149/month, Wegovy injection subscriptions at $249/month, and Zepbound at $299 to $449/month, the obesity market just entered its most competitive phase in history.
🏢 Corporate & Business Developments
Anthropic Pays $400M for a 10-Person Biotech AI Startup
What Happened: Anthropic acquired Coefficient Bio, a stealth AI biotech startup, for approximately $400 million in an all-stock deal (reported by The Information, confirmed by TechCrunch). Founded eight months ago by Samuel Stanton and Nathan Frey (both former Genentech Prescient Design), the team of fewer than 10 employees will join Anthropic's Health Care Life Sciences division. Against Anthropic's $380B post-money valuation, this represents roughly 0.1% dilution.
Executive Impact: Coming one week after Lilly's $2.75B Insilico deal, this reinforces that AI drug discovery is an active capital deployment category. Anthropic is now the only major AI lab with in-house pharmaceutical domain expertise at the model level. Sanofi, Novo Nordisk, and AbbVie already use Claude in their operations. Biology-specific features are expected within 12 to 18 months.
Takeda Exits 8-Year Dementia Partnership with Denali TAK | DNLI
What Happened: Takeda notified Denali on April 3 that it is terminating their collaboration on DNL593 (progranulin replacement for FTD-GRN). The partnership began in January 2018 with $150M upfront. Takeda stated the decision was strategic and not related to efficacy or safety data. Denali regains full rights. Phase 1/2 enrollment is complete (40 patients), with data expected by end of 2026.
Executive Impact: This is Takeda's latest portfolio simplification under incoming CEO Julie Kim, following the 634 U.S. job cuts, the $1.26B restructuring, and the positive zasocitinib data. Denali now bears all development costs alone but retains full IP and has a recently approved commercial product (Avlayah for Hunter syndrome).
🔬 Clinical & Research Updates
Global Pharma Pipeline Contracts for the First Time Since the 1990s
What Happened: Citeline's annual R&D report found 22,940 drugs in development at the start of 2026, a 3.9% decline from 23,875 in 2025. This is the first contraction since the mid-1990s. The pipeline had nearly quadrupled from 5,995 in 2001 to 23,875 in 2025. Oncology dropped from 9,476 to 9,036. Rare disease shrank from 7,721 to 7,618.
Executive Impact: The headline is dramatic but the nuance matters. The number of companies with active programs actually grew from 6,823 to 7,057. Phase 1, 2, and 3 pipeline sizes all increased, as did total drug launches. What's shrinking is the earliest-stage pipeline. Companies are killing preclinical candidates faster and concentrating resources on higher-conviction programs. The AI drug discovery wave is partly a response to this: if the industry is advancing fewer candidates, the selection process needs to be better.
📅 The Week Ahead
Now: Foundayo shipping through LillyDirect. Retail pharmacy rollout in progress.
April: Novo Nordisk Wegovy HD U.S. launch continues
April: Heart Rhythm 2026 conference
July 2026: Medicare Part D pricing for Foundayo ($50/month) targeted
H2 2026: Denali DNL593 Phase 1/2 FTD-GRN data
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
💊 Foundayo vs. Wegovy Pill: Full competitive comparison on dosing, convenience, pricing, weight loss data, and distribution
🧠 Anthropic's Life Sciences Bet: What $400M for 10 people tells you about the emerging economics of biology-native AI
📊 Pipeline Plateau: Why fewer drugs in development and more active companies is actually a healthy signal
🎯 Updated catalyst calendar
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here